Diligence memo · auto-generated · as of July 2, 2026
Talphera, Inc.
Talphera, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Talphera, Inc. operates in Pharmaceuticals, based in SAN MATEO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Talphera, Inc. has raised $97M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $21M on 2011-06-29.
Most recent recorded round closed around 2025-09-10.
Valuation (modeled)modeled
Provath models Talphera, Inc. at approximately $74M (range $36M–$106M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.67× the median modeled value of Series B Pharmaceuticals companies in 2025–2027 (17 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 10 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 3.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 91% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 49% of those peers.
Closest niche peers: Phlow Corp., AlphaTON Capital Corp, Triton Therapeutics, Inc., Sensorium Therapeutics, Inc., Belhaven Biopharma Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.